Journal Article

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Bachelot, Thomas, Conte, Pierfranco, Hart, Lowell L, Alba, Emilio, Favret, Anne M, Germa, Caroline, Souami, Farida, Yardley, Denise, Wist, Erik, Miller, Michelle, Sonke, Gabe S, Marschner, Norbert, Xuan, Fengjuan, O’Shaughnessy, Joyce, Jakobsen, Erik, Nusch, Arnd, Burris, Howard A, Paluch-Shimon, Shani, Verma, Sunil, Arteaga, Carlos L, Chan, Arlene, Burdaeva, Olga, Cameron, David A, Janni, Wolfgang, André, Fabrice, Hortobagyi, Gabriel N, Grischke, Eva-Maria, Stemmer, Salomon M, Petrakova, Katarina, Hirawat, Samit, Blackwell, Kimberly L, Tseng, Ling-Ming, Blau, Sibel, Yap, Yoon-Sim, Winer, Eric P, Campone, Mario, Villanueva, Cristian

2016

Overview

In patients with advanced HR-positive, HER2-negative breast cancer, the addition of the cyclin-dependent kinase inhibitor ribociclib to letrozole was associated with a significantly higher rate of progression-free survival than placebo. Up to 75% of breast cancers express the estrogen receptor or progesterone receptor (hormone-receptor [HR]–positive). 1 , 2 Endocrine therapy is the standard of care for postmenopausal women with advanced breast cancer that is HR-positive and human epidermal growth factor receptor 2 (HER2)–negative, with aromatase inhibitors being the preferred first-line treatment option. 3 , 4 However, in the majority of patients, resistance to currently available options eventually develops, which requires the administration of sequential therapy with alternative endocrine regimens. 4 – 8 Thus, the identification of effective treatment options that prolong or restore sensitivity to endocrine therapies is important. Cyclin-dependent kinases 4 and 6 (CDK4/6) in . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Aged / Aged, 80 and over / Aminopyridines - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Breast cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - pathology / Cancer therapies / Cyclin-dependent kinase 4 / Disease-Free Survival / Double-Blind Method / Drug Administration Schedule / Endocrine therapy / Epidermal growth factor / ErbB-2 protein / Estrogens / Female / Humans / Kaplan-Meier Estimate / Kinases / Letrozole / Leukopenia / Metastases / Metastasis / Middle Aged / Myelosuppression / Neoplasm Staging / Neutropenia / Nitriles - administration & dosage / Patients / Post-menopause / Proteins / Purines - administration & dosage / Receptor, ErbB-2 / Receptors, Estrogen / Receptors, Progesterone / Survival / Targeted cancer therapy / Triazoles - administration & dosage / Womens health